Locoregional cutaneous metastases of melanoma (LCMM) represent a therapeutic challenge. Many treatment options are available with varying results. The combination of cryotherapy and imiquimod, two treatments with a possible synergistic effect, has not yet been described for treating this disease. In this paper, we aimed to show the response of LCMM to cryotherapy combined with topical imiquimod 5%. A retrospective review of 20 patients diagnosed with LCMM and treated with cryotherapy combined with topical imiquimod 5% between November 2000 and May 2014 at three institutions was performed. The locoregional cutaneous response was evaluated. After a mean of five sessions, 13 patients (65%) responded to treatment, eight (40%) of these completely and five (25%) partially. Systemic disease progressed in 16 (80%) patients. Cryotherapy followed by topical imiquimod 5% is simple to apply, has minimal adverse effects and provides response rates similar to other, more complex treatment options.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/1346-8138.13197 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Recurrent primary cutaneous marginal zone lymphoma: a comparative study of initial tumours, recurrences, and outcomes in 61 patients.
Histopathology
December 2024
Pathology Department, CHU de Bordeaux, Bordeaux, France.
Article Synopsis
- - The study investigates primary cutaneous marginal zone lymphoma (PCMZL) by analyzing recurrent cases to determine whether it's a reactive process or a true lymphoma, utilizing data from the French Study Group of Cutaneous Lymphoma (GFELC).
- - Methods included assessing histology, B-cell clonality, and immunophenotype of lesions, revealing that most initial cases were localized, with differences in recurrence times based on location, and certain clonal patterns were more prominent in local recurrences.
- - The findings suggest that assessing immunoglobulin phenotype, particularly IgM and IgD, may be critical for diagnosing PCMZL, as IgM-positive cases tend to lead to more aggressive transformation and poorer prognosis, indicating different biological
Survival Outcomes in Patients Undergoing Pelvic Exenteration for Pelvic Mucosal Melanomas: Retrospective Single Institution Australian Study.
Dis Colon Rectum
December 2024
Department of Colorectal Surgery, Royal Prince Alfred Hospital, Sydney, Australia.
Background: Pelvic mucosal melanomas, including anorectal and urogenital melanomas, are rare and aggressive with a median overall survival of up to 20 months. Pelvic mucosal melanomas behave differently to its cutaneous counterparts and presents late with locoregional disease, making pelvic exenteration its only curative surgical option.
Objective: This study aimed to evaluate the survival outcomes post pelvic exenteration in pelvic mucosal melanomas at Royal Prince Alfred Hospital.
Talimogene laherparepvec (T-VEC) and Emerging Intralesional Immunotherapies for Metastatic Melanoma: A Review.
Curr Oncol Rep
December 2024
Department of Surgery, Division of Surgical Oncology, University of Vermont Medical Center, 111 Colchester Avenue, Burlington, VT, 05401, USA.
Purpose Of Review: As the incidence of cutaneous melanoma continues to rise worldwide, its heterogeneous presentation proves challenging for managing and preventing relapse.
Recent Findings: While surgery remains a mainstay in staging and treatment of locoregional metastatic melanoma, intralesional therapies have emerged as a new tool to treat unresectable in-transit and nodal metastases and reduce the risk of relapse through immunomodulatory mechanisms. In this review, we will provide an overview of intralesional therapies for melanoma with a particular focus on talimogene laherparepvec (T-VEC) and its future uses.
Management of unilateral neck irradiation in elderly patients with head and neck cancer: Which place for hypofractionation? A single-centre experience of 43 patients.
Cancer Radiother
December 2024
Department of Radiation Oncology, Institut de cancérologie de Lorraine, Vandœuvre-lès-Nancy, France.
Article Synopsis
- The study aimed to assess the safety and effectiveness of a specific radiation treatment for cervical lymph node cancers in older, frail patients, using a hypofractionated approach.
- A total of 43 patients were analyzed, primarily males with a median age of 83, receiving varying degrees of acute side effects from the treatment, with a majority experiencing radiodermatitis and some needing enteral nutrition.
- After treatment, about 26% of patients had a complete response to the radiation at a median follow-up of 9.2 months, with no severe long-term toxicity reported after three months.
[Sacituzumab govitecan in the second line treatment in a patient with triple-negative breast cancer with extensive locoregional recurrence.].
Recenti Prog Med
November 2024
Dipartimento di Oncoematologia, Uosd Oncologia medica, Policlinico "Tor Vergata", Roma.
Triple-negative breast cancer (TNBC) is a heterogeneous disease with an aggressive clinical course and worse outcomes than other breast cancer subtypes. Metastatic triple-negative breast cancer (mTNBC) is characterized by an aggressive clinical course and unfavorable outcomes, despite the pharmacological treatments used. The present clinical case describes a 35-year-old woman affected by TNBC characterized by rapid and subsequent local, cutaneous and lymph node progression of the disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!